Hanmi Science Co

Hanmi Science Co EBIT per Share

The EBIT per Share of Hanmi Science Co (008930.KS) as of Oct 10, 2026 is 898.29 KRW. In the previous year, EBIT per Share was 1,149.84 KRW — a change of -21.88% (lower).

EBIT per Share

898.29KRW

YoY

-21.88%

Last updated:

EBIT per Share of Hanmi Science Co is 2025 898.29 KRW. EBIT per Share of Hanmi Science Co was 2024 1,149.84 KRW. It decreases by -21.88% lower compared to the previous year.

The Hanmi Science Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2018
185.63 KRW
Jan 1, 2019
279.70 KRW
Jan 1, 2020
498.71 KRW
Jan 1, 2021
802.36 KRW
Jan 1, 2022
1,210.33 KRW
Jan 1, 2023
899.04 KRW
Jan 1, 2024
1,149.84 KRW
Jan 1, 2025
898.29 KRW
The Hanmi Science Co EBIT per Share history
YEAREBIT per ShareYoY
898.29KRW-21.88%
1,149.84KRW+27.90%
899.04KRW-25.72%
1,210.33KRW+50.85%
802.36KRW+60.89%
498.71KRW+78.31%
279.70KRW+50.67%
185.63KRW-16.34%
221.90KRW-4.69%
232.82KRW-89.96%
2,319.17KRW+1,482.53%
146.55KRW+36.21%
107.59KRW+64.50%
65.40KRW+34.99%
48.45KRW-67.50%
149.10KRW-87.05%
1,150.98KRW-10.65%
1,288.24KRW+1.09%
1,274.33KRW+21.50%
1,048.80KRW—
Access this data via the Eulerpool API

Hanmi Science Co Stock analysis

What does Hanmi Science Co do? Hanmi Science Co Ltd is a South Korean company specializing in the manufacturing of pharmaceutical products, biologics, and medical devices. The company was founded in 1973 as a chemical company and obtained the license for drug manufacturing in 1990, expanding its product range to include pharmaceuticals. Today, the company's business model includes three main areas: research and development, manufacturing and sales of drugs, and sales of medical devices. Hanmi aims to develop and produce innovative and high-quality products to improve people's health worldwide. In the field of research and development, Hanmi Science is a leading company. It specializes in the research and development of novel drugs and biologics. The company has an impressive track record in the development and marketing of innovative drugs for the treatment of diabetes, cancer, and rare diseases. This includes a range of biosimilars produced using biotechnological methods that are more affordable compared to original medical substances. Hanmi also has a state-of-the-art production infrastructure that meets the highest quality standards and ensures reliable supply. In the field of drug manufacturing, the company produces generics and biosimilars that are sold in more than 50 countries worldwide. Hanmi also specializes in the production of chemotherapeutics and parenteral drugs that have proven efficacy and safety. The medical device sales division focuses on marketing high-quality medical devices, including diagnostic and monitoring devices used in the medical field. Hanmi also distributes a range of medical consumables, including transfusion sets, syringes, infusion sets, and catheters. Hanmi Science Co Ltd offers a wide range of products that can be categorized into various categories. Among the pharmaceutical products are antidiabetic drugs, anticancer agents, antidepressants, antibiotics, antiviral medications, and products for the treatment of rare diseases. The portfolio also includes biosimilars of botulinum toxin, insulin, and humiderm among the biologics. Overall, Hanmi Science Co Ltd holds a strong position in the South Korean market and has also established a good reputation internationally. With its focus on research and development and the production of high-quality drugs and medical devices, the company has a promising future. Hanmi Science Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hanmi Science Co stock

EBIT per Share of Hanmi Science Co is 898.29 KRW in 2025.

EBIT per Share of Hanmi Science Co changed from 1,149.84 KRW to 898.29 KRW, representing a -21.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Hanmi Science Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

Income Statement — Hanmi Science Co

All Key Metrics — Hanmi Science Co